Christopher Lui
Christopher serves as CEO of Selesta, a unique boutique healthcare and life science firm dedicated to serving Asia’s emerging entrepreneurs and businesses.
He has 18+ years of experience covering Greater China and ASEAN healthcare in bulge bracket banks such as Morgan Stanley and Merrill Lynch, including regional investment banks such as CIMB and Fosun. He was last at Jefferies as a Managing Director, pioneering its Asia (ex-Japan/Australia) healthcare equity research efforts. He has participated in and led 40+ healthcare IPOs in HK and US. He also worked in a global healthcare specialist fund. Christopher has a BSc in Biochemistry and BSc in Mathematical Economics from the University of Wisconsin – Madison.
Christopher serves as CEO of Selesta, a unique boutique healthcare and life science firm dedicated to serving Asia’s emerging entrepreneurs and businesses.
He has 18+ years of experience covering Greater China and ASEAN healthcare in bulge bracket banks such as Morgan Stanley and Merrill Lynch, including regional investment banks such as CIMB and Fosun. He was last at Jefferies as a Managing Director, pioneering its Asia (ex-Japan/Australia) healthcare equity research efforts. He has participated in and led 40+ healthcare IPOs in HK and US. He also worked in a global healthcare specialist fund. Christopher has a BSc in Biochemistry and BSc in Mathematical Economics from the University of Wisconsin – Madison.
Articles: Christopher Lui
Asia Healthcare Weekly: 7th April 2025
APAC / This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers China’s USD 36.2bn in outbound licensing agreements, Henlius & EssexBio meeting Phase III endpoints, Organon acquiring US rights of tocilizumab biosimilar from Biogen, GE Healthcare’s acquisition of Japan’s Nihon Medi-Physics, Wuxi Biologics’ disposal of vaccine facility to Merck for USD 500mn, and…
Asia Healthcare Weekly: 31st March 2025
APAC / This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers the AACR 2025 ADC pipeline list from China, Puhe out-licensing global rights of a PRMT5 inhibitor to Bayer, AbbVie accusing Genmab of ADC trade secret theft on ADC technology used by ProfoundBio, and Singapore’s A*STAR investing in TW-based HoneyBear to accelerate ARC…
Latest Report
